NCT04662788View on ClinicalTrials.gov

Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2024

Study Completion Date

January 1, 2027

Conditions
Hematological Malignancies
Interventions
DRUG

NK cells/Combined Monoclonal Antibodies

Each subject receive NK cells/Combined Monoclonal Antibodies

Trial Locations (1)

Unknown

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER